Every 8-K that TriSalus Life Sciences, Inc. Warrant (TLSIW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TLSIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLSIW filings page.
TriSalus Life Sciences reported second quarter 2026 revenue of $11.4 million from TriNav system sales, up 1.7% year over year, with gross margin improving to 86.8% from 83.9% as unit costs declined. Operating loss widened to $9.8 million, and net loss attributable to common stockholders was $9.2 million, or $0.16 per share.
Non-GAAP adjusted EBITDA loss was $7.1 million, reflecting higher sales and marketing spending to expand the commercial organization, partly offset by lower research and development and general and administrative expenses. Cash and cash equivalents reached $46.3 million, supported by an equity offering, and total stockholders’ equity improved to $6.6 million from a deficit of $33.9 million at December 31, 2025.
The company maintained full-year 2026 revenue guidance of $54–$57 million, representing 19%–26% growth over 2025, and highlighted progress in its Pressure-Enabled Drug Delivery platform, including new real-world evidence in liver cancer, the PEDIR study submission, and ongoing Phase 1 trials of investigational immunotherapy nelitolimod.
TriSalus Life Sciences, Inc. reported the results of its Annual Meeting of Stockholders. A total of 41,728,676 shares of common stock, representing 67.9% of outstanding shares, were present or represented, providing a solid quorum for the meeting’s business.
Stockholders elected Mary Szela and Gary Gordon as directors to serve three-year terms expiring at the 2029 annual meeting. The appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026 was also ratified by a wide margin.
On executive compensation matters, stockholders approved a three-year frequency for future advisory votes on named executive officer pay, and approved the current compensation of named executive officers on an advisory basis. Following the vote, the Board decided the company will hold say-on-pay votes every three years.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million from its TriNav system, a 2.9% decrease from the same period in 2025, while gross margin improved to 86.2% from 83.7% as unit costs fell.
Operating loss widened slightly to $8.4 million, driven mainly by higher sales and marketing and stock-based compensation tied to commercial expansion. However, changes in the fair value of derivatives and earnout liabilities produced non-cash gains of $11.3 million, turning results into net income of $1.5 million, or $0.03 per share, versus a prior-year loss.
On a non-GAAP basis, adjusted EBITDA loss was $5.8 million, modestly higher than a year ago. The company raised $46.0 million in gross proceeds from an equity offering, ending March 31, 2026 with $56.6 million in cash and cash equivalents. Management revised 2026 revenue guidance to a range of $54 million to $57 million and highlighted ongoing clinical and commercial progress for its PEDD platform and nelitolimod program.
TriSalus Life Sciences, Inc. announced that Jodi Devlin has notified the company of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The company previously appointed Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, helping support continuity in its clinical and medical leadership.
TriSalus Life Sciences, Inc. appointed Richard Marshall, M.D. as Chief Medical Officer, effective June 29, 2026. He will move into this full-time role from his current position as Medical Director and will lead medical strategy, clinical development and evidence generation across the company’s oncology programs.
Under his offer letter, Dr. Marshall will receive an annual base salary of $525,000, a $250,000 sign-on bonus, and will be eligible for an annual bonus of up to 50% of base salary based on Board-determined goals. Following his start date, the Board will be asked to grant him 120,000 stock options and 60,000 restricted stock units, with further annual equity grants possible under the Equity Incentive Plan.
The accompanying press release highlights Dr. Marshall’s background in interventional oncology and his role in supporting TriSalus’ Pressure-Enabled Drug Delivery platform, TriNav devices and investigational immunotherapy nelitolimod as the company advances treatments for solid tumors.
TriSalus Life Sciences reported strong growth for 2025 but remained unprofitable. Revenue from the TriNav system reached $45.2 million for the year, up 53% from 2024, with fourth quarter revenue of $13.2 million, a 60% year-over-year increase and 14% sequential growth.
Full-year gross profit rose to $38.2 million, though gross margin edged down to 84.6%, reflecting launch-related manufacturing inefficiencies. Operating loss narrowed to $26.9 million, and adjusted EBITDA loss improved to $17.2 million. Net loss attributable to common stockholders expanded to $69.7 million, mainly due to preferred stock conversion-related items.
Cash and cash equivalents were $20.4 million as of December 31, 2025, and subsequent to year-end the company raised $46 million in gross proceeds via a public offering. Management reaffirmed 2026 revenue guidance of $60–62 million and highlighted continued commercial adoption of TriNav, higher gross margins in Q4 2025, and ongoing investments in clinical studies and new PEDD-based products.
TriSalus Life Sciences, Inc. has entered into an underwriting agreement for a public offering of 9,756,100 shares of its common stock at $4.10 per share. The company also granted underwriters a 30-day option to buy up to 1,463,415 additional shares to cover over-allotments.
Gross proceeds are expected to be about $40.0 million, with estimated net proceeds of approximately $37.0 million without exercising the option, or about $42.64 million if the option is fully exercised. TriSalus plans to use the cash for general corporate purposes, including capital spending, working capital, and administrative costs.
The deal is being made under an effective Form S-3 shelf registration, with Lake Street Capital Markets acting as sole book-runner. The offering is expected to close around February 23, 2026, and the company, its officers, directors, and a key securityholder have agreed to 90-day lock-up periods.